Neuro-APP Education Sessions
Neuroscience Advanced Practice Provider Educational Symposium (Neuro-APP): Advanced Care for Neuroscience Patients All times are in the Central time zone (CDT).
Sunday, March 16, 2025
Untangling the Web: Monoclonal Antibodies targeting β Amyloid in Mild Cognitive Impairment (MCI) and Mild Alzheimer’s Dementia (AD).
8:00 – 9:00 am CDT
Jennifer Woods, MSN CCNS CNRN SCRN
Pharmacology hours: 1
Anti-β amyloid therapies are novel drugs for the treatment of mild cognitive impairment (MCI) and mild Alzheimer’s Dementia (AD). There are specific criteria for utilization of the drugs they are not without inherent risk. While these drugs are utilized in the outpatient setting, the potential for amyloid related imaging abnormalities (ARIA) i.e. microhemorrhages have implications should a patient present to the emergency department with alterations in neurological status. As an advanced practice provider, it is imperative to understand the hypothesis of the pathophysiology of AD, the mechanism of action of anti-β amyloid therapies, and the inherent risks associated with the use of the therapies, and the treatment should complications arise.
Pediatric Cervical Spine Traumatic Injury. What to do, When it Happens
9:05 – 10:05 am CDT
Amanda Johnson, DNP, APRN, CPNP-PC/AC
Pediatric cervical spine injuries are low incidence but potentially high mortality if undiagnosed. The low incidence does not allow for providers to gain confidence in recognizing and understanding treatment strategies. Often neurosurgical providers are sought out as the experts in spinal injuries, but some might not have the exposure in clinical practice. Attend this session to learn and review pediatric cervical spine injuries in a non-threatening environment.
Get the Skinny on GLP-1 Agonists and Parkinson's Disease
10:20 am – 11:20 am CDT
Kara Zimcosky, APRN FNP-C CNRN
Patients with Parkinson’s Disease are always researching and asking questions about new treatments and medications to improve their quality of life. Neuroscience nurses, neurology nurse practitioners, and other healthcare professionals in the neuroscience field will have a better understanding of how GLP-1 agonists may benefit individuals diagnosed with PD and how GLP-1 agonists could potentially become another treatment option for PD in the near future. Since the management of Parkinson’s Disease is focused on symptomatic care, APPs in the neurology field are always searching for the best, evidence-based treatments to recommend to their PD patients.
Helping Patients Dance Again: Ventriculoperitoneal Shunt Use in Normal Pressure Hydrocephalus
11:25 am – 11:55 am CDT
Elaine Regacho, MSN, FNP-BC
NPH is commonly underdiagnosed, however it continues to affect the adult-geriatric population as this is a disease of aging. The use of programmable shunts in NPH patients is increasing, and neurology APP's will continue to encounter these devices in practice. Learn about neurology and adult-gerontology providers on normal pressure hydrocephalus including diagnosis and symptoms, the indications for surgical intervention/shunt placement, shunt mechanism of actions, and the role of the APP in managing shunts post-operatively.
Unraveling the Web: Carotid Web as a Rare Cause of Stroke in the Young
1:00 – 1:30 pm CDT
Courtney Bloss, MSPAS, PA-C
Pharmacology hours: 0.5
Define and understand carotid web and how it can affect our stroke patients, specifically young patients, and how we care for them. Attend this session to hear in-depth explainations of various treatment options for carotid web and the role they play in reducing recurrent stroke.
Fentanyl, Ketamine, and Psilocybin: The Neurological Effects and Why People are Dying
1:35 – 2:35 pm CDT
Marianne Beare Vyas, PHD ANP-BC CNRN
Pharmacology hours: 1
More information coming soon!
Outpatient Arginine Infusions as a Preventive Treatment for Stroke-Like Episodes in MELAS Syndrome
2:40 – 3:10 pm CDT
Heather Pomella, MSN, RN, CPNP, CNRN
Pharmacology hours: 0.5
Expand your knowledge about MELAS from a practitioners' perspective and learn about a novel treatment in MELAS that has shown efficacy in preventing stroke-like episodes.
Clipping, Coiling, Embolizing, Resecting and Revascularizing for Pediatric Cerebrovascular Disease
3:25– 4:25 pm CDT
Jennifer Judge, FNP, CNRN
Christopher Isibor, FNP-BC, CNRN
Attend this session to enhance your knowledge of the treatment of Pediatric Cerebrovascular diseases including Moyamoya, AVMs, Cavernous Malformations, aneurysms and more.
To Zap or Not to Zap? That is the Question: High Intensity Focused Ultrasound
4:30 – 5:00 pm CDT
Rachel Stouffer, MSN APRN CNRN
Learn all about initial Essential Tremor (ET) treatment, possible surgical treatment options, and appropriate referral to a movement center. Dig deep into specific details about the process and indications for High Intensity Focus Ultrasound (HIFU), as it is a relatively new treatment option for ET. Knowledge of this treatment plan will allow providers to identify appropriate patients to refer for surgical evaluation, utilizing the patient and healthcare resources.